AAA
OVID icon

Affinity Asset Advisors’s Ovid Therapeutics OVID Stock Holding History

Affinity Asset Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.6M Buy
10,636,318
+3,486,318
+49% +$6.23M 1.22% 27
2025
Q4 		$11.7M Buy
7,150,000
+4,500,000
+170% +$6.93M 0.66% 41
2025
Q3 		$3.44M Buy
2,650,000
+1,982,484
+297% +$1.72M 0.3% 61
2025
Q2 		$220K Hold
667,516
– – 0.03% 84
2025
Q1 		$208K Buy
+667,516
New +$410K 0.02% 91

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Affinity Asset Advisors's OVID Position: Q1 2026 in Review

Affinity Asset Advisors increased its Ovid Therapeutics (OVID) stake by 49% in Q1 2026, buying an estimated $6.23M and bringing the position to 10,636,318 shares worth $23.6M. The position accounts for 1.22% of the portfolio, ranked #27.

Affinity Asset Advisors first reported a position in OVID in Q1 2025 and has held it in 5 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Affinity Asset Advisors held 10,636,318 shares of Ovid Therapeutics worth $23.6M as of Q1 2026.
  • Affinity Asset Advisors bought 3,486,318 Ovid Therapeutics shares in Q1 2026, an estimated $6.23M.
  • Ovid Therapeutics made up 1.22% of Affinity Asset Advisors's portfolio in Q1 2026, its #27 holding.
  • Affinity Asset Advisors first reported a position in Ovid Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.